Published in J Invest Dermatol on November 01, 2008
Mutational status of naevus-associated melanomas. Br J Dermatol (2015) 2.68
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol (2009) 1.19
A melanoma molecular disease model. PLoS One (2011) 1.15
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol (2009) 1.10
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol (2012) 1.07
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res (2009) 0.98
Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog (2010) 0.97
Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem (2009) 0.95
Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. Oncol Lett (2014) 0.95
Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol (2011) 0.94
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget (2012) 0.94
Genetics and epigenetics of the skin meet deep sequence. J Invest Dermatol (2012) 0.93
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol (2010) 0.91
Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol (2009) 0.91
Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. Int J Nanomedicine (2013) 0.90
Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis (2012) 0.90
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
Expression and function of CD9 in melanoma cells. Mol Carcinog (2010) 0.89
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
A potent inhibitor of SIK2, 3, 3', 7-trihydroxy-4'-methoxyflavon (4'-O-methylfisetin), promotes melanogenesis in B16F10 melanoma cells. PLoS One (2011) 0.88
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. PLoS One (2013) 0.87
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87
Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res (2012) 0.85
Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses. Virology (2013) 0.85
Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid Based Complement Alternat Med (2013) 0.82
Use of gene expression and pathway signatures to characterize the complexity of human melanoma. Am J Pathol (2011) 0.81
12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s). J Biol Chem (2009) 0.79
Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J Exp Clin Cancer Res (2010) 0.79
The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78
Timosaponin AIII inhibits melanoma cell migration by suppressing COX-2 and in vivo tumor metastasis. Cancer Sci (2016) 0.78
Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. Transl Oncol (2013) 0.77
Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents. Bioorg Med Chem (2010) 0.76
pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda. BMC Clin Pathol (2009) 0.76
N-(4-methoxyphenyl) caffeamide-induced melanogenesis inhibition mechanisms. BMC Complement Altern Med (2017) 0.75
Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma. Melanoma Res (2017) 0.75
Melanoma: tumor microenvironment and new treatments. An Bras Dermatol (2017) 0.75
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat (2007) 2.35
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00
p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol (2011) 1.77
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One (2012) 1.76
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol (2009) 1.57
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30
The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. Arch Dermatol (2008) 1.28
Cutaneous melanomas associated with nevi. Arch Dermatol (2003) 1.27
Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst (2011) 1.17
A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer (2003) 1.17
Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol (2006) 1.17
Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res (2012) 1.17
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13
Small RNAs in development and disease. J Am Acad Dermatol (2008) 1.13
Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol (2005) 1.10
Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res (2010) 1.08
Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
EphA2 is an essential mediator of UV radiation-induced apoptosis. Cancer Res (2008) 1.02
Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer (2006) 1.01
Update on the Epidemiology of Melanoma. Curr Dermatol Rep (2013) 1.01
Melanoma and genetics. Clin Dermatol (2008) 0.98
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am (2009) 0.98
The genetics of skin cancer. Am J Med Genet C Semin Med Genet (2004) 0.98
Association between female breast cancer and cutaneous melanoma. Int J Cancer (2004) 0.98
The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol (2013) 0.97
Spitz nevi and other Spitzoid lesions part I. Background and diagnoses. J Am Acad Dermatol (2011) 0.96
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res (2013) 0.95
A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer (2008) 0.95
Pathways to melanoma. Semin Cutan Med Surg (2010) 0.92
X-chromosome inactivation and skin disease. J Invest Dermatol (2008) 0.92
A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol (2004) 0.91
Loss of xeroderma pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-deficient mice. Cancer Res (2007) 0.90
Dermal melanocytic proliferation with features of a plaque-type blue nevus and neurocristic hamartoma. J Am Acad Dermatol (2003) 0.89
Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol (2009) 0.88
Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med (2009) 0.88
A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds. J Invest Dermatol (2010) 0.87
Spitz nevi and other Spitzoid lesions part II. Natural history and management. J Am Acad Dermatol (2011) 0.87
Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol (2006) 0.85
Combined use of intense pulsed light and Q-switched ruby laser for complex dyspigmentation among Asian patients. Lasers Surg Med (2008) 0.85
Molecular therapeutic approaches to melanoma. Mol Aspects Med (2010) 0.84
Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. Hum Pathol (2012) 0.83
Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol (2012) 0.83
Cutaneous melanoma: family screening and genetic testing. Dermatol Ther (2006) 0.82
Melanoma susceptibility genes and risk assessment. Methods Mol Biol (2014) 0.82
Urgent access to a specialty care melanoma clinic is associated with a higher rate of melanoma detection. J Am Acad Dermatol (2011) 0.81
Technical considerations for follicular unit extraction in African-American hair. Dermatol Surg (2013) 0.81
Genetics for the practicing dermatologist. Semin Cutan Med Surg (2010) 0.80
Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg (2010) 0.80
Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg (2012) 0.80
Introduction to genetic association studies. J Invest Dermatol (2007) 0.79
Agminated segmental nevi demonstrating intranevic concordance of BRAF status. J Invest Dermatol (2010) 0.78
Dynamic gene expression analysis links melanocyte growth arrest with nevogenesis. Cancer Res (2009) 0.78
Phenotypic categorization of genetic skin diseases reveals new relations between phenotypes, genes and pathways. Bioinformatics (2009) 0.78
Melanoma genetics: the other side. Clin Dermatol (2013) 0.77
Long-term outcome of Spitz-type melanocytic tumors. Arch Dermatol (2011) 0.77
Recent updates on genetics: teaching old dogmas new tricks. Pediatr Dermatol (2008) 0.77
The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics (2007) 0.77
The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer (2007) 0.76
Aggressive skull base metastasis from uveal melanoma: a clinicopathologic study. Eur J Ophthalmol (2014) 0.75
Hereditary cancer syndromes of the skin. Clin Dermatol (2005) 0.75
Primer on the human genome. J Am Acad Dermatol (2007) 0.75
The distribution of microscopic melanoma metastases in sentinel lymph nodes: implications for pathology protocols. Am J Surg Pathol (2012) 0.75
Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation. Am J Dermatopathol (2017) 0.75
Martin C. Mihm, Jr and the history of the Pigmented Lesion Clinic at the Massachusetts General Hospital. J Cutan Pathol (2010) 0.75
Genodermatoses with cutaneous tumors and internal malignancies. Dermatol Clin (2008) 0.75